OCTOBER 28, 2005

PROHOST    FILTER

SOME GOOD BOOSTING NEWS

CHIRON (CHIR-NEWS) announced preliminary promising data from clinical study of its investigational vaccine against an H9N2 avian influenza strain that has infected a small number of people and may have the potential to cause a human pandemic.

READ MORE: Chiron Announces Promising Data from Clinical Study of Adjuvanted Avian Influenza Vaccine; Results Confirm Previous Clinical Studies: Chiron's MF59 Adjuvant Significantly Enhances Immune Response

In other news, Chiron received a $62.5 million contract to supply avian influenza vaccine for a U.S. stockpile, the company reported on Thursday. READ MORE: Chiron gets nod for U.S. flu stockpile

AMGEN (AMGN -  NEWS):  The firm announced that it has received the approval of European Commission for its Kepivance or Palifermin therapy, which is found to decrease the incidence, duration and severity of mouth sores in patients with blood cancers. In the European Union, about 13,000 cancer patients undergo autologous blood and bone marrow transplant each year.

READ MORE: Amgen Receives European Commission Approval For Kepivance Therapy To Treat Mouth Sores In Cancer Patients - Update

FLAMEL TECHNOLOGIES (FLML -NEWS): The firm announced that GlaxoSmithKline (GSK) has determined that successful Phase 3 clinical trial results have been obtained on a controlled release formulation of an already-marketed GSK drug using Flamel's Micropump™ technology. This determination by GSK will result in the payment of a $2 million milestone under a license agreement between the companies, which was entered into in March of 2003.

READ MORE: Flamel Technologies Announces Successful Phase III Results in Connection with its Collaboration with GlaxoSmithKline

PROHOST RESEARCH

P.O.BOX 640 429

Oakland Gardens, Ny 11364

Telephone : 516 678 1335

Fax 718 423 2731

E-mail prohost@aol.com.  

FORWARD-LOOKING STATEMENT Prohost is independent publication providing information on biotech companies. Prohost does not accept compensation from companies that are featured or profiled. It is strongly recommended that any purchase or sale decisions to any of the featured companies be discussed with a financial advisor or broker prior to completing any such purchase or sale decision. All statements or expressions are the opinion of Prohost and are not meant to be a solicitation or recommendation to buy, sell, or hold securities. Investing in embryonic companies, micro-cap and growth securities is highly speculative and carries a high degree of risk. It is possible that an investor can lose all of his/her investment in this type of companies that are profiled. The information that Prohost relies on is either through the profiled company, news services, research reports, interviews, or other outside sources that Prohost believes are reliable. Prohost makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure of the profiled companies and accepts no responsibilities for inaccuracies or misleading content in any material supplied by those clients. There can be no assurance that future events relating to the profiled company will occur as anticipated. The information contained herein is provided as an information service only. Past performance of featured companies does not guarantee the future success of any currently featured or profiled company. We encourage our readers to invest carefully and read the investor information provided by the Securities and Exchange Commission ("SEC") and/or the National Association of Securities Dealers ("NASD"). We also strongly recommend that you read the SEC advisory to investors concerning Internet Stock Fraud, which can be found at: http://www.sec.gov/consumer/cyberfr.htm